Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0T1GF
|
||||
| Former ID |
DCL000171
|
||||
| Drug Name |
MP470
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
SuperGen
|
||||
| Formula |
C23H21N5O3S
|
||||
| InChI |
InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32)
|
||||
| InChIKey |
FOFDIMHVKGYHRU-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 850879-09-3
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
16369229, 23453848, 42361725, 77946799, 99437047, 124757111, 125163915, 131480736, 134338846, 135263011, 135626621, 135685152, 135685153, 135685172, 136340107, 136367369, 136367870, 137275712, 137276002, 139988781, 143499562, 144116253, 152234887, 152258122, 160646961, 160708511, 162011866, 162037515, 162202665, 163782381, 164194061, 165247706, 174561001, 177748917, 186022477, 188899560, 198969243, 223387929, 223705031, 223972211, 226471652, 242059854, 243943799, 249565615, 252160959, 252215845, 252543326, 252671616
|
||||
| Target and Pathway | |||||
| Target(s) | Alpha platelet-derived growth factor receptor | Target Info | Modulator | [531617], [532785] | |
| Mast/stem cell growth factor receptor | Target Info | Modulator | [531617], [532785] | ||
| KEGG Pathway | MAPK signaling pathway | ||||
| Ras signaling pathway | |||||
| Rap1 signaling pathway | |||||
| Calcium signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| Focal adhesion | |||||
| Gap junction | |||||
| Regulation of actin cytoskeleton | |||||
| HTLV-I infection | |||||
| Pathways in cancer | |||||
| MicroRNAs in cancer | |||||
| Glioma | |||||
| Prostate cancer | |||||
| Melanoma | |||||
| Central carbon metabolism in cancer | |||||
| Choline metabolism in cancerhsa04014:Ras signaling pathway | |||||
| Hematopoietic cell lineage | |||||
| Melanogenesis | |||||
| Acute myeloid leukemia | |||||
| PANTHER Pathway | Angiogenesis | ||||
| PDGF signaling pathway | |||||
| WikiPathways | Regulation of Actin Cytoskeleton | ||||
| Osteoblast Signaling | |||||
| Focal Adhesion | |||||
| Hair Follicle Development: Organogenesis (Part 2 of 3) | |||||
| PIP3 activates AKT signaling | |||||
| Cardiac Progenitor Differentiation | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Allograft Rejection | |||||
| Signaling Pathways in Glioblastoma | |||||
| Signaling by PDGF | |||||
| AngiogenesisWP304:Kit receptor signaling pathway | |||||
| Differentiation Pathway | |||||
| Signaling by SCF-KIT | |||||
| miR-targeted genes in muscle cell - TarBase | |||||
| miR-targeted genes in lymphocytes - TarBase | |||||
| miR-targeted genes in epithelium - TarBase | |||||
| References | |||||
| Ref 531617 | The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination. Radiother Oncol. 2011 Oct;101(1):59-65. | ||||
| Ref 532785 | Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204. | ||||
| Ref 542847 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7932). | ||||
| Ref 531617 | The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination. Radiother Oncol. 2011 Oct;101(1):59-65. | ||||
| Ref 532785 | Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.